22 April 2025

N4 Pharma plc

 ("N4 Pharma" or the "Company")

Result of General Meeting

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that at the General Meeting ("GM"), held earlier today, all resolutions were duly passed.

The full text of all the resolutions can be found in the Notice of GM, a copy of which is available on the Company's website.

As a result of the passing of the resolutions, the Company has issued the 294,719,650 shares (the "Second Issue Shares"), the Fundraise Warrants and the Broker Warrants referred to in its announcement dated 1 April 2025.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for the Second Issue Shares to be admitted to trading on AIM, and it is expected that admission will become effective and trading will commence in the Second Issue Shares at 8.00 a.m. on or around 23 April 2025 ("Admission").

Following Admission, the total number of Ordinary Shares in the Company in issue will be 832,280,349. No shares are held in treasury, therefore the total number of voting rights in the Company following Admission will be 832,280,349 ("Total Voting Rights"). The Total Voting Rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

Capitalised terms used but not otherwise defined in this announcement shall have the meanings ascribed to such terms in the announcement dated 1 April 2025, unless the context requires otherwise.

-      Ends -

For more information please contact:

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set, and working towards first-in-human clinical data, to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.